Tazemetostat in advanced epithelioid sarcoma with loss of …

Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype. Over 90% of tumours have lost INI1 expression, leading to oncogenic dependence on the transcriptional repressor EZH2. In this study, we report the clinical activity and safety of tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma.

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30451-4/fulltext